Top Science

First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC – Top Science

Top Science shared on X:

“This is the first prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced Non- Small Cell Lung Cancer (NSCLC).

Sintilimab was efficacious and well-tolerated irrespective of PD-L1 expression level in patients with advanced NSCLC and had similar efficacy and safety to Pembrolizumab.”

First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC - Top Science First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC - Top Science

Additional information.
Source: Top Science/X

 

anti-PD-1 antibodies Bin Gan Bin-Chao Wang cancer Chong-Rui Xu E-E Ke Hai-Yan Tu Hong-Hong Yan Hua-Jun Chen Jia-Xin Lin Jia-Yi Deng Jie Huang Jin-Ji Yang Ming-Yi Yang Ming-Ying Zheng NSCLC OncoDaily Oncology pembrolizumab Qing Zhou Si-Yang Maggie Liu Sintilimab Top Science Wen-Zhao Zhong Xu-Chao Zhang Yang-Si Li Yangqiu Li Yi-Long Wu Zhen Wang